PAR Q4 FY26 results at a glance
PAR DRUGS AND CHEM LTD Q4 FY26 key results metrics| Quarter | Q4 FY26 |
|---|
| Quarter ended | 31 Mar 2026 |
|---|
| Revenue | ₹19.61 cr |
|---|
| Revenue YoY | -12.2% |
|---|
| Operating profit | ₹0.51 cr |
|---|
| Operating margin | 2.6% |
|---|
| Net profit | ₹0.85 cr |
|---|
| Net profit YoY | -48.3% |
|---|
| Net profit QoQ | -82.2% |
|---|
| Net margin | 4.4% |
|---|
| Basic EPS | ₹0.69 |
|---|
| TTM revenue | ₹104 cr |
|---|
| TTM net profit | ₹13.11 cr |
|---|
| TTM net margin | 12.6% |
|---|
PAR Q4 FY26 results: what the numbers say
PAR DRUGS AND CHEM LTD (PAR) has reported its Q4 FY26 results for the quarter ended 2026-03-31. The company posted revenue of ₹19.61 cr and a net profit of ₹0.85 cr, translating into earnings per share of ₹0.69.
Compared with the same quarter a year earlier, revenue declined by -12.2% and net profit declined strongly by -48.3%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹0.51 cr, an operating margin of 2.6% versus 6.8% a year ago — a contraction of 4.1 percentage points.
PAR quarter-wise results table
Revenue
₹19.61 cr
-12.2% YoY
Net profit
₹0.85 cr
-48.3% YoY
Operating profit
₹0.51 cr
-65.9% YoY
PAR DRUGS AND CHEM LTD (PAR) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q4 FY262026-03-31 | ₹19.61 cr | ₹0.51 cr | ₹0.85 cr | 2.6% | 4.4% | ₹0.69 | -48.3% | -82.2% |
| Q3 FY262025-12-31 | ₹29.34 cr | ₹5.13 cr | ₹4.8 cr | 17.5% | 16.4% | ₹3.90 | — | +16.2% |
| Q2 FY262025-09-30 | ₹28.66 cr | ₹5.13 cr | ₹4.13 cr | 17.9% | 14.4% | ₹3.36 | — | +24.1% |
| Q1 FY262025-06-30 | ₹26.05 cr | ₹2.66 cr | ₹3.33 cr | 10.2% | 12.8% | ₹2.70 | — | +101.6% |
| Q4 FY252025-03-31 | ₹22.33 cr | ₹1.51 cr | ₹1.65 cr | 6.8% | 7.4% | ₹1.34 | — | — |
| TTM (last 4 quarters) | ₹104 cr | ₹13.43 cr | ₹13.11 cr | 13.0% | 12.6% | ₹10.65 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
PAR quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
PAR DRUGS AND CHEM LTD quarterly income statement| Particulars | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹19.61 cr | ₹29.34 cr | ₹28.66 cr | ₹26.05 cr | ₹22.33 cr |
|---|
| Total expenses | ₹19.1 cr | ₹24.21 cr | ₹23.53 cr | ₹23.39 cr | ₹20.82 cr |
|---|
| Gross profit | ₹10.7 cr | ₹16.95 cr | ₹17.94 cr | ₹14.71 cr | ₹12.55 cr |
|---|
| Operating profit (EBIT) | ₹0.51 cr | ₹5.13 cr | ₹5.13 cr | ₹2.66 cr | ₹1.51 cr |
|---|
| Operating margin | 2.6% | 17.5% | 17.9% | 10.2% | 6.8% |
|---|
| Interest cost | ₹0.04 cr | ₹0.01 cr | ₹0.05 cr | ₹0.02 cr | ₹0.02 cr |
|---|
| Profit before tax | ₹0.83 cr | ₹6.44 cr | ₹5.55 cr | ₹4.48 cr | ₹2.28 cr |
|---|
| Tax expense | -₹0.02 cr | ₹1.64 cr | ₹1.42 cr | ₹1.15 cr | ₹0.63 cr |
|---|
| Effective tax rate | -2.7% | 25.5% | 25.6% | 25.7% | 27.5% |
|---|
| Net profit (PAT) | ₹0.85 cr | ₹4.8 cr | ₹4.13 cr | ₹3.33 cr | ₹1.65 cr |
|---|
| Net profit margin | 4.4% | 16.4% | 14.4% | 12.8% | 7.4% |
|---|
| Basic EPS | ₹0.69 | ₹3.90 | ₹3.36 | ₹2.70 | ₹1.34 |
|---|
| Diluted EPS | ₹0.69 | ₹3.90 | ₹3.36 | ₹2.70 | ₹1.34 |
|---|
PAR results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | -12.2% | — | — | — | — |
|---|
| Revenue QoQ | -33.2% | +2.4% | +10.0% | +16.6% | — |
|---|
| Operating profit YoY | -65.9% | — | — | — | — |
|---|
| Operating profit QoQ | -90.0% | +0.1% | +92.9% | +76.2% | — |
|---|
| Net profit YoY | -48.3% | — | — | — | — |
|---|
| Net profit QoQ | -82.2% | +16.2% | +24.1% | +101.6% | — |
|---|
| EPS YoY | -48.5% | — | — | — | — |
|---|
| EPS QoQ | -82.3% | +16.1% | +24.4% | +101.5% | — |
|---|
PAR annual results history
Full-year performance for PAR DRUGS AND CHEM LTD, useful for reading each quarter in context.
PAR DRUGS AND CHEM LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹103 cr | ₹101 cr | ₹95.11 cr | ₹95.1 cr |
|---|
| Total expenses | ₹89.96 cr | ₹84.88 cr | ₹74.94 cr | ₹80.54 cr |
|---|
| Gross profit | ₹30.42 cr | ₹32.77 cr | ₹36.22 cr | ₹28.69 cr |
|---|
| Operating profit (EBIT) | ₹12.83 cr | ₹15.67 cr | ₹20.16 cr | ₹14.56 cr |
|---|
| Operating margin | 12.5% | 15.6% | 21.2% | 15.3% |
|---|
| Interest cost | ₹0 cr | ₹0 cr | ₹0 cr | ₹0 cr |
|---|
| Profit before tax | ₹17.3 cr | ₹17.92 cr | ₹19.52 cr | ₹15.08 cr |
|---|
| Tax expense | ₹4.19 cr | ₹4.57 cr | ₹5.02 cr | ₹3.75 cr |
|---|
| Effective tax rate | 24.2% | 25.5% | 25.7% | 24.8% |
|---|
| Net profit (PAT) | ₹13.11 cr | ₹13.36 cr | ₹14.5 cr | ₹11.33 cr |
|---|
| Net profit margin | 12.8% | 13.3% | 15.2% | 11.9% |
|---|
| Basic EPS | — | ₹10.86 | ₹11.78 | ₹9.21 |
|---|
| Diluted EPS | — | ₹10.86 | ₹11.78 | ₹9.21 |
|---|
Revenue trend and demand read-through
Topline for Q4 FY26 came in at ₹19.61 cr against ₹22.33 cr in Q4 FY25, and ₹29.34 cr in the preceding Q3 FY26 quarter.
On a sequential basis revenue declined -33.2%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹19.1 cr, or 97.4% of revenue, with operating profit declined -65.9% year on year.
Margins, tax and profitability
Net profit of ₹0.85 cr works out to a net margin of 4.4% compared with 7.4% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, PAR DRUGS AND CHEM LTD reported profit before tax of ₹0.83 cr, a tax charge of -₹0.02 cr (effective rate -2.7%), interest cost of ₹0.04 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹4.8 cr in Q3 FY26 to ₹0.85 cr in Q4 FY26, a change of -82.2%.
Trailing twelve months and annual context
Across the trailing four quarters PAR DRUGS AND CHEM LTD has generated revenue of ₹104 cr and net profit of ₹13.11 cr, a trailing net margin of 12.6%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹103 cr with net profit of ₹13.11 cr and EPS of —, versus the prior year where revenue grew +2.2% and profit declined -1.9%.
What to watch in the next PAR quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
PAR DRUGS AND CHEM LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
PAR results coverage
No results report published for PAR yet — our desk covers each quarter within minutes of the filing.
PAR quarterly results FAQs
What were PAR DRUGS AND CHEM LTD (PAR) Q4 FY26 results?
In Q4 FY26 (quarter ended 31 Mar 2026), PAR DRUGS AND CHEM LTD reported revenue of ₹19.61 cr and net profit of ₹0.85 cr, a change of -48.3% year on year on -12.2% revenue growth. EPS stood at ₹0.69.
What is PAR profit margin in Q4 FY26?
PAR DRUGS AND CHEM LTD posted a net profit margin of 4.4% and an operating margin of 2.6% in Q4 FY26. On a trailing twelve-month basis, revenue is ₹104 cr and net profit ₹13.11 cr.
Did PAR results beat the previous quarter?
PAR DRUGS AND CHEM LTD net profit changed -82.2% quarter on quarter, from ₹4.8 cr in Q3 FY26 to ₹0.85 cr in Q4 FY26.
When are PAR DRUGS AND CHEM LTD (PAR) quarterly results?
PAR DRUGS AND CHEM LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see PAR latest quarterly results?
Results coverage for PAR will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the PAR stock page.
What is PAR DRUGS AND CHEM LTD annual revenue and profit?
For FY26, PAR DRUGS AND CHEM LTD reported full-year revenue of ₹103 cr and net profit of ₹13.11 cr, with EPS of —.
How many quarterly results has PAR declared recently?
Past results dates for PAR will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
